Noronha, V., Ramaswamy, A., Patil, V.M., Joshi, A., Chougule, A., Kane, S., Kumar, R., Sahu, A., Doshi, V., Nayak, L., Mahajan, A., Janu, A. and Prabhash, K. (2016) ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country. PLOS ONE, 11, e0160752. (Erratum in: PLOS ONE, 11, e0168221).
https://doi.org/10.1371/journal.pone.0160752
https://www.cancerresearchuk.org/about-cancer/coping/physically/cancer-and-the-risk-of-blood-clots

has been cited by the following article:

• TITLE: The Need for a National Guideline for the Management of NSCLC ALK-Positive Lung Cancer in the UK: Results of Patient-Driven Surveys

  AUTHORS: Debra Montague

  KEYWORDS: ALK-Positive, Non-Small Cell Lung Cancer, Oncogene-Driven, Guidelines

  JOURNAL NAME: Journal of Cancer Therapy, Vol.13 No.7, July 28, 2022

  ABSTRACT: Introduction: There are currently no national guidelines specifically for the management of NSCLC ALK-positive lung cancer in the UK. National guidelines exist for lung cancer in general and reference is made to ALK-positive lung cancer. However, the generic nature of these guidelines is not sufficient for the optimal management of this specific type of lung cancer, with its unique disease management requirements. Method: In 2021, members of the charity ALK POSITIVE LUNG CANCER (UK) completed anonymised surveys to gather real-world data about their treatment. Results: Data were gathered on the prescribing of blood thinners (n = 127); frequency of brain MRI scans (n = 123); prescribing bone strengthening medication (n = 127); frequency of CT scans (n = 123); mental health (n = 132). There was significant variation in each of these five aspects of treatment. Conclusions: The findings, from a representative population of ALK-positive patients, provide new information on the significant disparities in the treatment that patients receive. This health inequality is likely to have a detrimental effect on the survival outcomes for some of these patients. It would improve patient outcomes and overall survival if ALK-positive lung cancer disease management national guidelines were established and utilised across the NHS in the UK. The evidence presented.